

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUPIN LTD. and LUPIN PHARMACEUTICALS INC.
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD.
Patent Owner

Inter Partes Review No.: Unassigned

DECLARATION OF M. JAYNE LAWRENCE, PH.D

Contents

I.	INTRODUCTION.....	6
II.	QUALIFICATIONS.....	6
III.	MATERIALS REVIEWED	11
IV.	LEGAL STANDARDS.....	11
V.	SUMMARY OF OPINIONS.....	18
	A. Claims 1-30 of U.S. Patent No. 8,669,290 are invalid as obvious	18
	B. Claims 1-30 of U.S. Patent No. 8,754,131 are invalid as obvious	20
	C. Claims 1-27 of U.S. Patent No. 8,871,813 are invalid as obvious	22
	D. Claims 1-30 of U.S. Patent No. 8,927,606 are invalid as obvious	23
VI.	AQUEOUS FORMULATION DEVELOPMENT FOR OPHTHALMIC USE.....	25
	A. General approach to formulation development	25
	B. NSAIDs were known and approved for ophthalmic use	28
	C. Formulation strategies for NSAIDs.....	33
	D. Formulation strategies for bromfenac	37
VII.	DETAILED DESCRIPTION OF THE PRIOR ART.....	39
	A. The '225 patent –U.S. Patent No. 4,910,225 (EX 1010).....	39
	B. EP '984 – EP 0 306 984 A1 (EX 1014)	40
	C. The '913 patent –U.S. Patent No. 5,891,913 (EX 1021).....	43
VIII.	DETAILED OPINIONS.....	45
	A. U.S. Patent No. 8,669,290.....	45
	1. Level of Skill in the Art.....	45
	2. Claim Construction.....	45
	3. Claims 1–30 of the '290 Patent	45
	4. The Specification of the '290 Patent	48
	5. Summary of the Prosecution History of the '290 Patent.....	49
	6. All Claims of the '290 Patent are Obvious Over the '225 Patent in View of EP '984.....	51
	a. Independent Claim 1	52
	b. Independent Claim 8	56
	c. Independent Claim 14	58
	d. Stability (claims 10, 20, and 22).....	59
	e. Pharmacologically Acceptable Salts (claims 2, 3, 9, 15, 16, and 21)	62

f.	pH (claims 6, 12, 18, and 24)	64
g.	Concentration of Components (claims 4, 5, 7, 11, 13, 17, 19, 23, and 25).....	65
h.	Preservative Efficacy Standard (claims 26-30).....	72
7.	All Claims of the ‘290 Patent are Obvious Over the ‘913 Patent in View of The ‘225 Patent	76
a.	Independent Claim 1	76
b.	Independent Claim 8	78
c.	Independent Claim 14	80
d.	Stability (claims 10, 20, and 22).....	81
e.	Pharmacologically Acceptable Salts (claims 2, 3, 9, 15, 16, and 21)	83
f.	pH (claims 6, 12, 18, and 24)	84
g.	Concentration of Components (claims 4, 5, 7, 11, 13, 17, 19, 23, and 25).....	86
h.	Preservative Efficacy Standard (claims 26-30).....	91
8.	Objective Indicia of Nonobviousness.....	93
a.	Other Objective Indicia	101
B.	U.S. Patent No. 8,754,131	104
1.	Level of Skill in the Art.....	104
2.	Claim Construction.....	104
3.	Claims 1-30 of the ’131 Patent.....	104
4.	The Specification of the ’131 Patent	107
5.	Summary of the Prosecution History of the ’131 Patent.....	108
6.	All Claims of the ‘131 Patent are Obvious Over the ‘225 Patent in View of EP ‘984.....	108
a.	Independent claims (claims 1, 7, and 13).....	108
b.	Stability (claims 9, 19, and 21).....	115
c.	Pharmacologically Acceptable Salts (claims 2, 3, 8, 14, 15, and 20)	117
d.	pH (claims 5, 11, 17, and 23)	119
e.	Concentration of Components (claims 4, 6, 10, 12, 16, 18, 22, and 24).....	121
f.	Preservative Efficacy Standard of US Pharmacopoeia (claims 25 – 29).....	126
g.	Formulation Additives (claim 30)	129

7.	All Claims of the ‘131 Patent are Obvious Over the ‘913 Patent in View of The ‘225 Patent	130
a.	Independent Claims (claims 1, 7, and 13)	130
b.	Stability (claims 9, 19, and 21).....	135
c.	Pharmacologically Acceptable Salts (claims 2, 3, 8, 14, 15, and 20)	138
d.	pH (claims 5, 11, 17, and 23)	140
e.	Concentration of Components (claims 4, 6, 10, 12, 16, 18, 22, and 24).....	141
f.	Preservative Efficacy Standard of US Pharmacopoeia (claims 25 – 29).....	145
g.	Formulation Additives (claim 30)	146
8.	Objective Indicia of Nonobviousness.....	147
C.	U.S. Patent No. 8,871,813	150
1.	Level of Skill in the Art.....	150
2.	Claim Construction.....	150
3.	Claims 1-27 of the ’813 Patent.....	150
4.	The Specification of the ’813 Patent	154
5.	Summary of the Prosecution History of the ’813 Patent.....	154
6.	All Claims of the ‘813 Patent are Obvious Over the ‘225 Patent in View of EP ‘984.....	155
a.	Independent Claims (claims 1, 7, and 13)	155
b.	Stability (claims 9, 19, and 20).....	162
c.	Pharmacologically Acceptable Salts (claims 2, 3, 8, 14, and 15)	165
d.	pH (claims 5, 11, 17, and 22)	166
e.	Concentration of Components (claims 4, 6, 10, 12, 16, 18, 21, and 23).....	168
f.	No Preservatives (claims 24 – 26).....	174
g.	Formulation Additives (claim 27)	175
7.	All Claims of the ‘813 Patent are Obvious Over the ‘913 Patent in View of The ‘225 Patent	176
a.	Independent Claims (claims 1, 7, and 13)	176
b.	Stability (claims 9, 19, and 20).....	182
c.	Pharmacologically Acceptable Salts (claims 2, 3, 8, 14, and 15)	184
d.	pH (claims 5, 11, 17, and 22)	186

e.	Concentration of Components (claims 4, 6, 10, 12, 16, 18, 21, and 23).....	187
f.	No Preservatives (claims 24 – 26).....	192
g.	Formulation Additives (claim 27).....	193
8.	Objective Indicia of Nonobviousness.....	193
D.	U.S. Patent No. 8,927,606.....	196
1.	Level of Skill in the Art.....	196
2.	Claim Construction.....	196
3.	Claims 1-30 of the '606 Patent.....	196
4.	The Specification of the '606 Patent.....	200
5.	Summary of the Prosecution History of the '606 Patent.....	200
6.	All Claims of the '606 Patent are Obvious Over the '225 Patent in View of EP '984.....	201
a.	Independent Claims (claims 1, 11, and 19).....	201
b.	Disease Indications (claims 2, 3, 13, 14, 20, and 21).....	208
c.	Dosage Information (claim 10).....	210
d.	Stability (claims 12 and 26).....	211
e.	Pharmacologically Acceptable Salts (claims 4, 7, 17, and 22).....	213
f.	Concentration of Components (claims 5, 6, 8, 9, 15, 16, 18, 23, 24, 25, and 27).....	215
g.	Preservative Efficacy Standard of EP-criteria B (claims 28 – 30).....	221
7.	All Claims of the '606 Patent are Obvious Over the '913 Patent in View of The '225 Patent.....	224
a.	Independent Claims (claims 1, 11, and 19).....	224
b.	Disease Indications (claims 2, 3, 13, 14, 20, and 21).....	228
c.	Dosage Information (claim 10).....	230
d.	Stability (claims 12 and 26).....	230
e.	Pharmacologically Acceptable Salts (claims 4, 7, 17, and 22).....	232
f.	Concentration of Components (dependent claims 5, 6, 8, 9, 15, 16, 18, 23, 24, 25, and 27).....	234
g.	Preservative Efficacy Standard of EP-criteria B (claims 28 – 30).....	240
8.	Objective Indicia of Nonobviousness.....	241

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.